Spiro R C, Parsons W G, Perry S K, Caulfield J P, Hein A, Reisfeld R A, Harper J R, Austen K F, Stevens R L
J Biol Chem. 1986 Apr 15;261(11):5121-9.
Cultured human melanoma M21 cells were treated with diethylcarbamazine (DEC), an inhibitor of proteoglycan biosynthesis in rat chondrosarcoma cells, to examine the assembly and transport of a chondroitin sulfate proteoglycan to the plasma membrane. Pretreatment of melanoma cells at 37 degrees C for 15 min with increasing doses of DEC followed by a 60-min pulse with [35S]sulfate in the presence of DEC resulted in a dose-related inhibition of incorporation of [35S]sulfate into macromolecules. In cells incubated for 75 min with both 1 mM beta-D-xyloside and 15 mM DEC, synthesis and secretion of beta-D-xyloside-bound 35S-glycosaminoglycans were inhibited by more than 80% as compared to cells treated with beta-D-xyloside alone; this inhibition was reversible. As assessed by [3H]serine incorporation into protein, overall protein synthesis was not substantially inhibited by DEC treatment. Detergent lysates from [35S]methionine-labeled melanoma cells were incubated with a monoclonal antibody (9.2.27) that specifically recognizes the peptide core of the melanoma proteoglycan. As assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the immunoprecipitate, a 240,000 Mr endoglycosidase H (Endo-H)-sensitive intermediate was the only form of the proteoglycan present inside the cells when the cultures were treated for 60-120 min with 10-15 mM DEC. When the melanoma cells were incubated for 10 min with 15 mM DEC and 100 mu Ci/ml of [35S]methionine, washed, and then chased for 15 min to 4 h in radioactive-free medium, the 240,000 Mr Endo-H-sensitive intermediate was slowly converted to a 250,000 Endo-H-resistant intermediate but not to a mature proteoglycan molecule that possessed chondroitin sulfate glycosaminoglycans. SDS-PAGE analysis of cell surface immunoprecipitates revealed that only a small amount of the 250,000 Mr intermediate was transported to the plasma membrane within 5 h of incubation in the presence of DEC. Proteoglycan synthesis was also inhibited when the melanoma cells were incubated for 60-120 min with ammonium chloride, but unlike DEC-treated cells the majority of the synthesized peptide core was converted to a 245,000 Mr Endo-H-resistant intermediate that was detected on the cell surface. Light and electron microscopic analysis of DEC-treated melanoma cells revealed large vacuoles and a distended Golgi and endoplasmic reticulum. Ammonium chloride-treated cells contained fewer vacuoles than DEC-treated cells but more vacuoles than normal cells.(ABSTRACT TRUNCATED AT 400 WORDS)
用二乙氨基甲嗪(DEC)处理培养的人黑色素瘤M21细胞,DEC是大鼠软骨肉瘤细胞中蛋白聚糖生物合成的抑制剂,以研究硫酸软骨素蛋白聚糖向质膜的组装和转运。在37℃下用递增剂量的DEC预处理黑色素瘤细胞15分钟,然后在DEC存在下用[35S]硫酸盐脉冲60分钟,导致[35S]硫酸盐掺入大分子的剂量相关抑制。在同时用1 mMβ-D-木糖苷和15 mM DEC孵育75分钟的细胞中,与仅用β-D-木糖苷处理的细胞相比,β-D-木糖苷结合的35S-糖胺聚糖的合成和分泌受到超过80%的抑制;这种抑制是可逆的。通过[3H]丝氨酸掺入蛋白质评估,DEC处理并未显著抑制总体蛋白质合成。来自[35S]甲硫氨酸标记的黑色素瘤细胞的去污剂裂解物与特异性识别黑色素瘤蛋白聚糖肽核心的单克隆抗体(9.2.27)一起孵育。通过免疫沉淀物的十二烷基硫酸钠-聚丙烯酰胺凝胶电泳评估,当培养物用10-15 mM DEC处理60-120分钟时,240,000 Mr的内切糖苷酶H(Endo-H)敏感中间体是细胞内存在的蛋白聚糖的唯一形式。当黑色素瘤细胞与15 mM DEC和100μCi/ml的[35S]甲硫氨酸孵育10分钟,洗涤,然后在无放射性培养基中追踪15分钟至4小时时,240,000 Mr的Endo-H敏感中间体缓慢转化为250,000的Endo-H抗性中间体,但未转化为具有硫酸软骨素糖胺聚糖的成熟蛋白聚糖分子。细胞表面免疫沉淀物的SDS-PAGE分析显示,在DEC存在下孵育5小时内,只有少量250,000 Mr的中间体转运到质膜。当黑色素瘤细胞与氯化铵孵育60-120分钟时,蛋白聚糖合成也受到抑制,但与DEC处理的细胞不同,大多数合成的肽核心转化为在细胞表面检测到的245,000 Mr的Endo-H抗性中间体。对DEC处理的黑色素瘤细胞的光镜和电镜分析显示有大液泡以及扩张的高尔基体和内质网。氯化铵处理的细胞比DEC处理的细胞含有更少的液泡,但比正常细胞含有更多的液泡。(摘要截断于400字)